Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting DNA Damage Response in Prostate and Breast Cancer
Antje M. Wengner, Arne Scholz, Bernard Haendler
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 8273-8273
Open Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy
Ruixue Huang, Ping‐Kun Zhou
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 515
DNA Damage and Its Role in Cancer Therapeutics
Jaeyoung Moon, Ichiwa Kitty, Kusuma Renata, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4741-4741
Open Access | Times Cited: 42
Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment
Fabio Raith, Daniel H. O’Donovan, Clara Lemos, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2289-2289
Open Access | Times Cited: 25
Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis
Tatsuo Sugawara, Ekaterina Nevedomskaya, Simon Heller, et al.
Molecular Oncology (2024) Vol. 18, Iss. 3, pp. 726-742
Open Access | Times Cited: 10
Advances in PARP Inhibitors for Prostate Cancer
Steven Tisseverasinghe, Boris Bahoric, Maurice Anidjar, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1849-1849
Open Access | Times Cited: 18
A review of non-classical MAPK family member, MAPK4: A pivotal player in cancer development and therapeutic intervention
Yaping Yan, Tengkun Dai, Mengmeng Guo, et al.
International Journal of Biological Macromolecules (2024) Vol. 271, pp. 132686-132686
Closed Access | Times Cited: 6
From Omics to Multi-Omics Approaches for In-Depth Analysis of the Molecular Mechanisms of Prostate Cancer
Ekaterina Nevedomskaya, Bernard Haendler
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 11, pp. 6281-6281
Open Access | Times Cited: 23
Targeting the stimulator of interferon genes (STING) in breast cancer
MA Ying-rui, Bai Bu-Fan, Liu Deng, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 16
Targeting the DNA Damage Response for Cancer Therapy
Ruoxi Wang, Yating Sun, Chunshuang Li, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 21, pp. 15907-15907
Open Access | Times Cited: 16
Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends
Chalermrat Kaewput, Sobhan Vinjamuri
Journal of Clinical Medicine (2022) Vol. 11, Iss. 10, pp. 2738-2738
Open Access | Times Cited: 21
Sex disparities in DNA damage response pathways: Novel determinants in cancer formation and therapy
Miriana Cardano, Giacomo Buscemi, Laura Zannini
iScience (2022) Vol. 25, Iss. 3, pp. 103875-103875
Open Access | Times Cited: 19
Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients
Bruna Dalmasso, Alberto Puccini, Fabio Catalano, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 4709-4709
Open Access | Times Cited: 19
Two birds with one stone: triple negative breast cancer therapy by PtCo bimetallic nanozyme coated with gemcitabine-hyaluronic acid-polyethylene glycol
Majid Sharifi, Rasoul Kheradmandi, Morteza Alizadeh
Cancer Nanotechnology (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 11
The KRAS, ATR and CHEK1 expression levels in endometrial cancer are the risk factors predicting recurrence
Liubov Buchynska, Inna Gordiienko, N.М. Glushchenko, et al.
PLoS ONE (2024) Vol. 19, Iss. 4, pp. e0302075-e0302075
Open Access | Times Cited: 4
DNA damage response-related signatures characterize the immune landscape and predict the prognosis of HCC via integrating single-cell and bulk RNA-sequencing
Hanqi Li, Yu Shi, Yue Li, et al.
International Immunopharmacology (2024) Vol. 137, pp. 112475-112475
Open Access | Times Cited: 4
Unraveling the genetic connections for mitochondrial DNA control region and breast cancer susceptibility
N. Khalid, Muhammad Umer Khan, Raima Rehman, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Role of Signaling Pathways Regulating Genomic Stability in Cancer
A. Sheikh, G. A. Bhat, Sukhdeep Kumar, et al.
(2025), pp. 395-435
Closed Access
Comprehensive analysis of PPPCs family reveals the clinical significance of PPP1CA and PPP4C in breast cancer
Wenjun Xie, Ying Sun, Yu Zeng, et al.
Bioengineered (2021) Vol. 13, Iss. 1, pp. 190-205
Open Access | Times Cited: 25
Studying the impact of chitosan salicylaldehyde/schiff base/CuFe2O4 in PC3 cells via theoretical studies and inhibition of PI3K/AKT/mTOR signalling
Ghada H. Elsayed, Asmaa M. Fahim
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
NEK kinases in cell cycle regulation, DNA damage response, and cancer progression
Joy T. Folahan, Nektarios Barabutis
Tissue and Cell (2025) Vol. 94, pp. 102811-102811
Closed Access
Werner syndrome exonuclease promotes gut regeneration and causes age-associated gut hyperplasia in Drosophila
Kun Wu, Juanyu Zhou, Yiming Tang, et al.
PLoS Biology (2025) Vol. 23, Iss. 4, pp. e3003121-e3003121
Open Access
Derivation and Application of Molecular Signatures to Prostate Cancer: Opportunities and Challenges
Dimitrios Doultsinos, Ian G. Mills
Cancers (2021) Vol. 13, Iss. 3, pp. 495-495
Open Access | Times Cited: 21
Construction of a DNA damage repair gene signature for predicting prognosis and immune response in breast cancer
Yi‐Ming Chang, Zhiyuan Huang, Hong Quan, et al.
Frontiers in Oncology (2023) Vol. 12
Open Access | Times Cited: 8
A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancer
Jinghui Liu, Yue Zhao, Daheng He, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 4, pp. 101015-101015
Open Access | Times Cited: 8
Circulating tumor biomarkers in early-stage breast cancer: characteristics, detection, and clinical developments
Jie Qiu, Da Qian, Yuancong Jiang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top